Nuvo and Galderma Win FDA Approval for Topical Peel

Nuvo Research announced that the FDA has approved its Pliaglis product, a topical anesthetic cream designed to minimize pain during aesthetic dermatological procedures such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. The approval comes on the heels of a Complete Response Letter issued by the FDA earlier this year, which raised issues that Nuvo and Galderma (its partner on Pliaglis) have successfully addressed. Pliaglis uses Nuvo's proprietary phase-changing technology to form a pliable peel on the skin when exposed to air. Earlier this year, Galderma stated that several European countries have approved Pliaglis, suggesting a global launch of the product by year-end.